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Histological Scoring for Small Lung Adenocarcinomas 2 cm
or Less in Diameter
A Reliable Prognostic Indicator
Akiko Miyagi Maeshima, MD,* Naobumi Tochigi, MD,*† Akihiko Yoshida, MD,*‡
Hisao Asamura, MD,§ Koji Tsuta, MD,* and Hitoshi Tsuda, MD*
Objective: Lung adenocarcinomas 2 cm or less in diameter were
studied to develop histologic criteria predicting the outcome.
Materials and Methods: We reviewed 510 consecutive lung ade-
nocarcinomas 2 cm or less in diameter and assessed three histologic
parameters to implement a histologic scoring system: lymphovas-
cular invasion, maximum diameter of the nonbronchioloalveolar
carcinoma (BAC) component, and percentage of the solid, cribri-
form, and/or papillary component in the entire tumor volume (%solid/
cribriform/papillary). One point was given to each of lymphovascular
invasion-positive, non-BAC 10 mm and %solid/cribriform/papillary
30%, and by the sum of these points, a score of 0 to 3 was assigned
for each tumor. We also evaluated minimally invasive adenocarcino-
mas comprising non-BAC 5 mm, Sakurai grades 1 and 2.
Results: Five-year disease-free survival rates of 287 patients with a
histologic score of 0, 69 with a score of 1, 64 with a score of 2, and
90 with a score of 3 were 98.9%, 92.4%, 78.4%, and 54.0%,
respectively. The 510 tumors included 129 noninvasive and 127
minimally invasive adenocarcinomas. None of these tumors re-
curred. In remaining 254 patients with overtly invasive adenocarci-
nomas, 5-year disease-free survival rates in 51 with a histologic
score of 0, 49 with a score of 1, 64 with a score of 2, and 90 with
a score of 3 were 95.9%, 89.2%, 79.4%, and 54.2%, respectively.
Conclusion: The histologic scoring system comprising lymphovas-
cular invasion-positive, non-BAC 10 mm and %solid/cribriform/
papillary 30% is able to predict the outcome of lung adenocarci-
nomas 2 cm or less in diameter not only in all cases but also in
overtly invasive adenocarcinomas. Minimally invasive adenocarci-
nomas did not recur in this large series.
Key Words: Small adenocarcinoma, Lung, Vessel invasion, Non-
BAC size, %solid/cribriform/papillary, Scoring.
(J Thorac Oncol. 2010;5: 333–339)
Adenocarcinoma is the most frequent histologic type oflung cancer.1 Because small peripheral adenocarcinomas
are frequently encountered in Japan, the validity of limited
surgery (segmentectomy or partial lung resection) for such
tumors has recently been proposed. To qualify the need for
limited surgery, it is mandatory to identify accurately low-
and high-risk group of patients with small adenocarcinomas.
A number of histologic prognostic factors for small
(3 or2 cm) adenocarcinomas have been reported. Tumor,
node, metastasis stage2 is the most important prognostic
factor,3 even for small adenocarcinomas. Motoi et al.,4 using
predominant subtypes modified from the 2004 World Health
Organization (WHO) classification,5 recently reported that
predominantly solid adenocarcinoma had a poor prognosis. It
has also been reported that a predominantly papillary pattern
or a certain amount of micropapillary pattern predicts poor
outcome.6,7
In our institution, Shimosato et al.8 reported scar grade
in 1980, and Maeshima et al.9 modified the scar grade in
2002. Kurokawa et al.10 proposed “early” adenocarcinoma
with no vascular invasion, low mitotic index, and lower scar
grade (grade 1 or 2). Noguchi et al.11 reported a 100% 5-year
survival rate for patients with bronchioloalveolar carcinoma
(BAC) and BAC with collapse, and a poor prognosis for pure
solid, acinar (cribriform), and papillary adenocarcinoma. Yo-
kose et al.12 examined adenocarcinomas 3 cm or less in diameter
and proposed an unfavorable subgroup showing vascular inva-
sion or a papillary growth component exceeding 25%.
Previously proposed features of minimally invasive ade-
nocarcinoma have included collapse and/or scar 5 mm,13
invasion5 mm,14 and Sakurai grades 1 and 2.15 Sakurai et al.15
assessed adenocarcinomas 2 cm or less in diameter and demon-
strated 100% 5-year disease-free survival rate in patients whose
tumors showed stromal invasion in the area of bronchioloalveo-
lar growth (grade 1) or stromal invasion localized at the periph-
ery of a fibrotic focus (grade 2). Grade 1 tumors resemble BAC,
and grade 2 tumors resemble BAC with collapse.
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In this study, we tried to clarify histologic risk factors
of small lung adenocarcinomas by using a combination of
three factors, which potentially helps define a subgroup
benefiting best from the limited surgery: lymphovascular
invasion, maximum diameter of the non-BAC component,
and percentage of the solid, cribriform and/or papillary com-
ponent in the entire tumor volume (%solid/cribriform/papil-
lary). Moreover, we performed an additional examination for
minimally invasive adenocarcinomas comprising a non-BAC
component 5 mm or less in diameter (non-BAC 5 mm),
Sakurai grades 1 and 2. The goal of this study was to stratify
small lung adenocarcinomas 2 cm or less in diameter to
predict outcome by using this histologic scoring system and
clarify the criteria for minimally invasive and noninvasive
adenocarcinomas.
PATIENTS AND METHODS
Patients
The study subjects were 510 consecutive adenocarci-
nomas of the lung 20 mm or less in diameter, surgically
resected at the National Cancer Center Hospital, Japan, be-
tween 1997 and 2003. Clinical information was extracted
from the medical records. Patients with synchronous multiple
lung cancers were excluded. Four hundred one patients un-
derwent lobectomy or more with complete lymph node dis-
section, 24 segmentectomy with lymph node sampling, and
85 segmentectomy or partial lung resection without lymph
node dissection. Limited surgery was performed if tumors
showed pure ground glass opacity by computed tomography
or if patients had some clinical risks. All resected materials
were pathologically proved to be free of tumor cells at the
surgical margins. Tumor, node, metastasis stages were deter-
mined according to the Union Internationale Contre le Cancer
(International Union Against Cancer) staging system,2 except
in patients without lymph node dissection. None of the
patients received adjuvant treatment.
Pathologic Review
The materials were fixed in 10% formalin overnight.
Tumors 20 mm or less (range: 5–20 mm) in diameter were cut
at 5 mm intervals, which meant that one to four slides were
prepared form each tumor according to size; i.e., one slide
was made from a tumor 5 mm in diameter, two slides from a
tumor 10 mm in diameter, three slides from a tumor 15 mm
in diameter, and four slides from a tumor 20 mm in diameter.
All slides of each tumor were observed for judgment of BAC
or invasive adenocarcinoma.
We evaluated the prognostic impact of several histo-
logic parameters, including lymphovascular invasion, maxi-
mum diameter of the non-BAC component, and %solid/
cribriform/papillary. Histologic parameters were assessed
after representative hematoxylin and eosin (HE)- and elast-
ica-stained tumor slides had been reviewed. Overt lymphatic
permeation and/or vascular invasion was judged to be lym-
phovascular invasion-positive and negative or suspicious but
not definite as lymphovascular invasion negative.
The maximum diameter of the non-BAC component
was measured on HE slides, because the definition of “inva-
sion” is challenging, in terms of judgments of alveolar float-
ing or filling tumor cells and collapse and/or scar (collapse/
scar). For example, some pathologists consider alveolar
floating or filling tumor cells showing a solid/cribriform/
papillary pattern to represent invasion, whereas others con-
sider this to represent noninvasion. The judgment of collapse/
scar versus invasion with an acinar pattern is also problematic.
Therefore, we simply measured the area that was not BAC. We
considered non-BAC to include the area containing frank inva-
sion (papillary, acinar, or solid component with a desmoplastic
reaction), collapse, scar without tumor cells, and alveolar float-
ing/filling tumor cells with micropapillary, cribriform, or solid
pattern.
Because adenocarcinoma with a predominantly solid,
cribriform, papillary, or micropapillary component was re-
ported to have a poor prognosis,4,6,7,11 the total percentage of
these components in the entire tumor volume (%solid/cribri-
form/papillary) was measured semiquantitatively. One point
was assigned for tumors showing each of lymphovascular
invasion-positive, non-BAC 10 mm, and %solid/cribri-
form/papillary 30%, to give a total of 0 to 3 points (Table
1). According to the histologic score given by the sum of the
points, clinical outcomes were compared.
We also evaluated the prognosis of noninvasive adeno-
carcinoma comprising BAC and BAC with collapse and
minimally invasive adenocarcioma comprising non-BAC 5
mm, Sakurai grades 1 and 2. Simultaneously, we evaluated
the scar grade,8 the Noguchi classification,11 and the 2004
WHO predominant subtype.4
Statistical Analysis
Five-year disease-free survival rates were calculated by
the Kaplan-Meier method. Differences in survival curves
were compared using the log-rank test. Multivariate analysis
was performed using Cox proportional hazards analysis.
Differences were considered significant at p  0.05.
RESULTS
Patient Characteristics
The patients’ clinicopathological features are summa-
rized in Table 2. Outcome was better in patients who under-
went limited surgery than in those who underwent lobectomy
or more (p 0.0360), perhaps due to the fact that many of the
tumors showing predominantly ground glass opacity by com-
TABLE 1. Histological Scoring System for Small Lung
Adenocarcinoma
A. Lymphovascular invasion Positive 1 point
Negative 0 point
B. Non-BAC size 10 mm 1 point
10 mm 0 point
C. %solid/cribriform/papillary 30% 1 point
30% 0 point
A  B  C 0–3 points
BAC, bronchioloalveolar carcinoma; %solid/cribriform/papillary, percentage of
solid, cribriform, and/or papillary component in the entire tumor volume.
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puted tomography were treated by limited surgery. All the
patients who underwent lobectomy or more (401 patients)
and those who underwent segmentectomy with lymph node
sampling (21 patients) were evaluable for pathologic stage:
347 tumors were p-stage IA, five were IB, 26 were IIA, five
were IIB, 26 were IIIA, 11 were IIIB, and two were IV.
Five-year disease-free survival rate for 510 patients was
87.6%. Tumors recurred in 66 patients. The sites of initial
recurrence were the lung in 20 patients, hilar, mediastinal, or
cervical lymph nodes in 17, bone in 18, pleura in 11, brain in
12, liver in two, adrenal gland in two, and spleen in one.
Because the tumors in this study ranged from 5 to 20 mm in
diameter, we compared patient survivals among three tumor
size groups: tumors 5 to 10 mm in diameter (99 cases),
tumors 10 to15 mm in diameter (187 cases), and tumors 15
to 20 mm in diameter (224 cases), and the 5-year disease-
free survival rates for these groups were 96.7%, 88.3%, and
83.2%, respectively. The survival rates for patients with
tumors 5 to 10 mm in diameter and those with 15 to 20
mm in diameter differed significantly.
Histologic Examinations
The correlation of histologic parameters and clinical
outcome of all 510 patients are summarized in Tables 3 and
4. Five-year disease-free survival rate was 97.9% in the 361
patients who were lymphovascular invasion-negative and
62.6% in the 149 patients who were lymphovascular inva-
sion-positive. Patients with lymphovascular invasion positiv-
ity had a significantly worse outcome than those with nega-
tivity (p  0.0001). Non-BAC size was 0 mm in 61 patients,
0 to 5 mm in 122, 5 to 10 mm in 180, and 10 mm in
147, the respective 5-year disease-free survival rate being
100%, 100%, 91.0%, and 67.7%. Among 122 tumors with a
non-BAC component of 0 to 5 mm, 42 were BAC with
collapse and 80 were invasive adenocarcinomas; none of these
tumors recurred. Five-year disease-free survival rate in patients
with non-BAC10 mm had a significantly worse outcome than
those with non-BAC 5 to 10 mm (p  0.0001).
%Solid/cribriform/papillary was 30% in 339 patients
and 30% in 171, with 5-year disease-free survival rate of
96.9% and 68.9%, respectively, the latter being significantly
worse than the former (p 0.0001). Five-year disease-free
survival rate was examined in relation to %solid/cribriform/
papillary using a cut-off value of 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, and 90%, and the 30% cut off was found to
have the highest statistical significance (data not shown).
Five-year disease-free survival rate was 98.9% in 287
patients with a histologic score of 0, 92.4% in 69 patients
TABLE 2. Patient Characteristics
Parameter
No. of
Patients (%)
5-yr Disease-Free
Survival (%) P
Total 510 87.6
Gender
Male 230 (45) 86.2 NS
Female 280 (55) 88.9
Age (yr, median)
23–89 (62)
Operation
Lobectomy or more 401 (79) 85.4 0.0361
Segmentectomy 25 (5) 95.8
Partial lung resection 84 (16) 96.2
Pathological stagea
I 352 (83) 93.7 0.0001
II–IV 70 (17) 46.9
Tumor size
5 to 10 mm 99 (19) 96.7 0.0040
10 to 15 mm 187 (37) 88.3
15 to 20 mm 224 (44) 83.2
Lymph node metastasisa
Negative 356 (84) 92.6 0.0001
Positive 66 (16) 49.2
Lymphovascular invasion
Negative 361 (71) 97.9 0.0001
Positive 149 (29) 62.6
Scar grade
1 75 (15) 100
2 139 (27) 99.3 0.0001
3 285 (56) 79.5
4 11 (2) 67.5
Noguchi classification
Types A–B 129 (25) 100
Type C 323 (63) 85.8 0.0001
Type D 34 (7) 78.4
Type E 10 (2) 58.3
Type F 14 (3) 61.2
WHO predominant subtype
BAC 353 (69) 95.4 0.0001
Acinar 22 (4) 68.3
Papillary 58 (12) 69.0
Solid 77 (15) 70.8
a Among 422 patients treated by lymph node dissection.
WHO, World Health Organization; NS, not significant.
TABLE 3. Correlation of Histological Parameters and Score
with Clinical Outcome in All 510 Patients with Small Lung
Adenocarcinoma
Parameters Subgroups
No. of
Patients (%)
5-yr Disease-Free
Survival (%) P
Total 510 87.6
Lymphovascular
invasion
Negative 361 (71) 97.9 0.0001
Positive 149 (29) 62.6
Non-BAC size
(mm)
0 61 (12) 100
0 to 5 122 (24) 100
5 to 10 180 (35) 91.0 0.0001
10 147 (29) 67.7
%solid/cribriform/
papillary
30 339 (66) 96.9 0.0001
30 171 (34) 68.9
Histological score 0 287 (56) 98.9
1 69 (13) 92.4 0.0001
2 64 (13) 78.4
3 90 (18) 54.0
BAC, bronchioloalveolar carcinoma; %solid/cribriform/papillary, percentage of
solid, cribriform, and/or papillary component in the entire tumor volume.
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with a score of 1, 78.4% in 64 patients with a score of 2, and
54.0% in 90 patients with a score of 3. Five-year disease-free
survival rate in patients with histologic scores of 2 and 3 was
worse than that of patients with scores of 0 and 1 (p0.0001)
(Figures 1 and 2).
Among the 510 tumors, 61 were classified as BAC, 68 as
BAC with collapse, 80 as invasive adenocarcinoma with non-
BAC5 mm, 10 as Sakurai grade 1, and 80 as Sakurai grade 2
(Table 4). Among 80 invasive adenocarcinomas with non-BAC
5 mm, two showed lymphovascular invasion-positive and three
had %solid/cribriform/papillary30%. Minimally invasive cat-
egories were not mutually exclusive. All 10 Sakurai grade 1
tumors showed non-BAC5 mm and were able to be included
in the category of non-BAC 5 mm. Among 80 Sakurai grade
2 tumors, 33 showed non-BAC5 mm, 38 showed non-BAC 5
to 10 mm, and nine showed non-BAC 10 mm. None of
Sakurai grade 1 or 2 tumors showed lymphovascular invasion-
positive or %solid/cribriform/papillary 30%.
Among 254 overtly invasive adenocarcinomas after
excluding the above-mentioned noninvasive and minimally
invasive adenocarcinomas, 5-year disease-free survival rate
was 96% in 51 patients with a tumor score of 0, 89% in 49
patients with a tumor score of 1, 78% in 64 patients with a
tumor score of 2, and 54% in 90 patients with a tumor score
of 3. (Figure 3) Because 5-year disease-free survival rates
differed significantly between tumors with histologic scores
of 0 and 1, and those of 2 and 3 (p  0.0001), the present
histologic scoring system seems to be useful for risk evalu-
ation of overtly invasive adenocarcinomas.
Simultaneously, the scar grade,8 the Noguchi classifi-
cation,11 and the WHO predominant subtype4 were examined
by univariate analysis (Table 2). Scar grade was able to
predict the outcome of patients with adenocarcinomas 2 cm
or less in diameter. Use of the Noguchi classification revealed
that patients with types D, E, and F tumors had a worse
prognosis than those with type C tumors (p  0.0001).
However, the numbers of type D, E, and F tumors were
relatively small, and the majority were classified as type C.
Among the total of 58 types D, E, and F tumors, four scored
1, 15 scored 2, and 39 scored 3, and thus, the majority were
classified a score of 2 or 3. Use of the WHO predominant
subtype revealed that patients with BAC-predominant tumors
had a better outcome than the others (p  0.0001). Multivar-
iate analysis showed that histologic score, pathologic stage,
lymph node metastasis, and WHO predominant subtype were
statistically significant (Table 5).
DISCUSSION
Recently, adenocarcinoma has become the most fre-
quent histologic type of lung cancer.1 Because small adeno-
carcinomas are frequently encountered in Japan, the validity
of limited surgery has recently been proposed. Risk assess-
ment of detailed histologic examination of small adenocarci-
nomas is needed to qualify the adequacy of limited surgery.
It has been reported that approximately 20% of adeno-
carcinomas 20 mm or less in diameter had lymph node
metastasis.16 In this study, 16% of a total of 510 adenocar-
cinomas 20 mm or less in diameter has lymph node metas-
tasis, which was slightly lower than in the previous reports.
Although the 5-year disease-free survival of patients with
adenocarcinomas 20 mm or less in diameter has not been
sufficiently assessed, Sakurai et al.15 reported a figure of
76.4% on the bases of 380 cases. The patients in this study
had a 5-year disease-free survival of 87.6%, which was a
higher rate than that reported by Sakurai et al.
A number of reports have addressed the outcome of
BAC. For resected localized BAC, the 5-year disease-free
survival rate was reported to be 73% by Volpino et al.17 in
2001, 74% by Breathnach et al.18 in 2001, and 81% by Rena
et al.19 in 2003. At our institution, the survival of patients
with localized BAC was reported to be 100% by Sakurai et
al.15 in 2004 and Maeshima et al.9 in 2003. A data have
indicated that the survival of patients with BAC improved
after revision of the BAC criteria in the 1999 WHO classifi-
cation, which defined BAC only as pure BAC, not including
mixed adenocarcinoma with a BAC component.20
We were able to verify several prior reports. As shown
in Table 2, scar grade proposed by Shimosato et al.8 was able
to predict the outcome of patients with adenocarcinomas 2 cm
or less in diameter. However, there were some problems in
that, a proportion of papillary adenocarcinomas, a high-risk
subgroup, were included as scar grade 1 tumors. Therefore, a
small number of grade 1 tumors recurred. In addition, dis-
tinction between grades 2 and 3 was not clear.
The Noguchi classification11 was also able to predict
the outcome of patients with small adenocarcinomas, because
types D, E, and F tumors showed a worse outcome than the
others. However, the majority of small adenocarcinomas
were classified as type C, and thus subclassification of type C
tumors does seem necessary. Although original article by
Noguchi et al. included invasive adenocarcinomas with lym-
TABLE 4. Survival of Patients with BAC, Minimally Invasive,
and Overtly Invasive Adenocarcinoma
Invasiveness
No. of
Patients (%)
5-yr Disease-Free
Survival (%) P
Total 510 87.6
Noninvasive
adenocarcinoma
129 (25) 100
BAC 61 (12)
BAC with collapse 68 (13)
Minimally invasive
adenocarcinomaa
127 (25) 100
Non-BAC 5 mm 80 (16)
Sakurai grade 1 10 (2)
Sakurai grade 2 80 (16)
Overtly invasive
adenocarcinoma
254 (50) 75.7
Histological score 0 51 (10) 95.9
Histological score 1 49 (10) 89.2 0.0001
Histological score 2 64 (12) 79.4
Histological score 3 90 (18) 54.2
a Minimally invasive categories were not mutually exclusive but rather different
ways of stratification. All the Sakurai grade 1 tumors and 41% (33/80) of the Sakurai
grade 2 tumors simultaneously fulfilled the criteria of non-BAC 5 mm.
BAC, bronchioloalveolar carcinoma.
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phovascular or pleural invasion in almost 10% of types A and
B tumors, in this study, BAC and BAC with collapse included
only noninvasive adenocarcinomas. We also assessed the
WHO predominant subtype.4 The BAC-predominant subtype
was the largest subtype and showed a better prognosis than
the others. Because most tumors have been classified as the
BAC-predominant subtype in Japanese series, subclassifica-
tion of this subtype is needed.
In this study, we performed histologic prognostic sub-
classification of small adenocarcinomas using three indica-
tors. Simultaneously, we performed an additional examina-
tion for prognostic implication of minimally invasive
adenocarcinoma proposed by our institution previously. Non-
BAC 5 mm, which is a modification of 5 mm collapse/
scar13 and 5 mm invasion,14 Sakurai grades 1 and 2,15 was
assessed using a larger series.
Kurokawa et al.10 and Yokose et al.12 reported that
vascular invasion was a poor prognostic indicator in small
adenocarcinomas. Because we considered that lymphovascu-
lar invasion was one of the results of invasion and reflected
metastatic potential, we assumed that it must be the most
important prognostic indicator.
FIGURE 1. Histology of Sakurai grades 1 and 2 and a histologic score 3 tumor. A, Sakurai grade 1 resembles bronchioloal-
veolar carcinoma (BAC) in low-power view (hematoxylin and eosin [HE], 40). B, Sakurai grade 1 has a small invasive focus in
the alveolar area (HE, 400). C, Sakurai grade 2 resembles BAC with collapse in low-power view (HE, 40). D, Sakurai grade
2 shows a fibroblastic reaction only at the interface between BAC and collapse (HE, 200). E, F, An example of a score 3 tu-
mor. The tumor shows non-BAC 10 mm, %solid/cribriform/papillary 30% (E, HE, 12.5), and lymphovascular invasion
positivity (F, HE, 100). Both scar and a papillary component were counted as non-BAC.
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Noguchi et al.11 reported that pure solid, acinar (crib-
riform), or papillary adenocarcinoma had poor prognosis.
Motoi et al.4 reported that the solid-predominant subtype had
a poor prognosis on the basis of the 2004 WHO predominant
subtype classification. Moreover, predominantly, papillary
adenocarcinoma7 and adenocarcinoma with a certain amount
of micropapillary pattern6 have been reported to have a poor
prognosis. Therefore, we considered all the papillary (includ-
ing micropapillary) cribriform, and solid components to be
poor prognostic factors possibly indicative of invasive quality
and assessed %solid/cribriform/papillary.
The size of invasion is also a prognostic indicator, as
shown in reports of modified scar grade,9 5 mm invasion,14
6 mm invasion,21 and 5 mm collapse/scar13 and may reflect
invasive quantity. However, because definition of invasion and
collapse/scar is somewhat obscure, we examined non-BAC size,
which includes frank invasion, scar/collapse, and alveolar float-
ing/filling tumor cells. We considered that assessment of these
three indicators in combination—lymphovascular invasion, non-
BAC size, and %solid/cribriform/papillary—could predict out-
come in detail and examined them by using a large series.
Three indicators of poor prognosis, lymphovascular
invasion-positive, non-BAC 10 mm, and %solid/cribri-
form/papillary 30%, were used to assign a score that would
subclassify and predict outcome in patients with small ade-
nocarcinomas. The scoring system was also applied to 254
overtly invasive adenocarcinomas after excluding BAC, BAC
with collapse, and minimally invasive adenocarcinoma. Be-
cause the patient group with a histologic score of 0 had 95.9%
5-year disease-free survival rate, the validity of limited sur-
gery for that group may be qualified. Patients with a histo-
logic score of 1 might also be candidates for limited surgery,
whereas patients with scores of 2 and 3 should not undergo
limited surgery from the viewpoint of high recurrence risk.
We reevaluated minimally invasive adenocarcinomas
reported from our institution using a larger series. None of 80
patients with invasive adenocarcinomas with non-BAC 5
mm suffered recurrence. However, as two cases with non-
BAC5 mm were lymphovascular invasion positive, a small
number of non-BAC 5 mm tumors might have metastatic
potential, and therefore, careful follow-up will be needed in
the future. Also, none of 10 patients with Sakurai grades 1
and 80 patients with Sakurai grade 2 suffered recurrence.
From these results, as reported from our institution previ-
ously, we concluded that tumors with non-BAC 5 mm,
Sakurai grade 1 or 2 can be considered minimally invasive
adenocarcinomas. However, because all cases of Sakurai
grade 1 simultaneously fulfilled the criteria of non-BAC 5
mm, only non-BAC 5 mm and Sakurai grade 2 should be
retained as minimally invasive adenocarcinoma. Finally, in
this study, we gained an impression that surgical specimens
of noninvasive and minimally invasive adenocarcinoma had
been increasing recently.
From our findings, we are able to derive two main
conclusions. First, the outcome of patients with adenocarci-
nomas 2 cm or less in diameter is predictable by using the
histologic scoring system comprising lymphovascular inva-
sion-positive, non-BAC10 mm and %solid/cribriform/pap-
illary 30%. Second, it was reconfirmed that patients whose
FIGURE 2. Survival curves for all 510 patients stratified by
histologic score.
FIGURE 3. Survival curves for 242 patients with overtly in-
vasive adenocarcinomas stratified by histologic score.
TABLE 5. Results of Multivariate Analysis Using the Cox
Proportional Hazards Model
Variables P HR 95% CI
Histological score 0.0001 3.175 2.093–4.816
Pathological stage 0.0001 4.005 2.455–6.534
Lymph node metastasis 0.0210 1.341 1.137–1.850
WHO predominant classification 0.0232 1.743 1.575–1.960
Gender, age, operation method, tumor size, scar grade, and Noguchi classification
were also examined, but these variables were not selected.
HR, hazard ratio; CI, confidence interval.
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tumors had non-BAC 5 mm, Sakurai grades 1 and 2
showed 100% survival. Patients with noninvasive, minimally
invasive, or histologic score 0 adenocarcinomas may be
candidates for limited surgery, whereas it seems problematic
to conduct limited surgery for histologic score 2 or 3 adeno-
carcinomas. The histologic scoring system and minimally
invasive categories might be useful only for small adenocar-
cinomas.
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